Targeted treatment up front improves survival for advanced prostate cancer, and we predict a change in thinking for precision cancer medicine.
The chemotherapy drug capecitabine gives patients a better quality of life and is as effective at preventing breast cancer from returning as the alternative CMF
Two drugs targeting different gene faults in lung cancer have shown potential to be better than those already available.
We take a look at results from the STAMPEDE clinical trial, which is researching how to improve treatment for men with prostate cancer.
A drug that’s already approved to treat certain ovarian cancers holds some advanced breast cancers at bay longer than standard chemotherapy.
Offering abiraterone (Zytiga) up-front with standard hormone treatment extends survival in men whose prostate cancer has spread.
Adding abiraterone to hormone therapy at the start of treatment for prostate cancer improves survival by 37 per cent.
We speak to Jane Hair, a biobanker involved in the National Lung Matrix Trial, about what her job involves.
We speak to Amanda Watson, research nurse on the National Lung Matrix Trial, about what her job involves.
We speak to Susie Brown, Trial Coordinator on the National Lung Matrix Trial, about what her job involves.